Cargando…

Safety and BNT162b2 mRNA COVID-19 vaccination

Detalles Bibliográficos
Autores principales:	Joob, Beuy, Wiwanitkit, Viroj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2021
Materias:	E-Letters: Comments and Responses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823579/ https://www.ncbi.nlm.nih.gov/pubmed/35075060 http://dx.doi.org/10.23750/abm.v92i6.12359

Ejemplares similares

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Patients with type 2 diabetes mellitus and response to COVID-19 BNT162b2 mRNA vaccine: correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
por: Waissengrin, Barliz, et al.
Publicado: (2021)

COVID-19 and Recurrent Status Epilepticus
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Polymorphism of tmprss2 (rs12329760) and severity of COVID-19 in the Ukrainian population: comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

COVID-19, Vaccination, Multisystem Inflammatory Syndrome, Aneurysm, Screening and Post Vaccination Death
por: Joob, Beuy, et al.
Publicado: (2023)

Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19
por: Joob, Beuy, et al.
Publicado: (2021)

Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
por: Niebel, Dennis, et al.
Publicado: (2021)

COVID-19 Vaccination and Usefulness in Prevention of Mortality Among the Elderly: An Analysis
por: Joob, Beuy, et al.
Publicado: (2023)

Cancerous Patient, COVID-19 Vaccination, Blood Viscosity and Stroke-Like Complication
por: Joob, Beuy, et al.
Publicado: (2023)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Cytokine Receptor Allele Frequency, Immunogenicity, and Efficacy of New COVID-19 Vaccine in Different Setting
por: Joob, Beuy, et al.
Publicado: (2023)

New COVID-19 Variant, VUI-202012/01: Molecular Change, Epitope Alteration, and Implication for Vaccine Efficacy
por: Joob, Beuy, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Expected efficacy of HPV vaccine in prevention of cervix cancer in Thailand
por: Joob, Beuy, et al.
Publicado: (2014)

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2022)

Immune thrombocytopenic purpura and COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2023)

Immune thrombocytopenic purpura and COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2023)

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2022)

Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
por: Duran, M.
Publicado: (2022)

COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years
por: Strumann, Christoph, et al.
Publicado: (2023)

CYP1A1 M2 (A2455G) Polymorphism with Susceptibility to Breast Cancer
por: Joob, Beuy, et al.
Publicado: (2020)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021)

Response to “Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases”
por: Lim, Ziying Vanessa, et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms and B-Cell Non-Hodgkin Lymphoma
por: Joob, Beuy, et al.
Publicado: (2018)

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
por: Yanay, Noa Berar, et al.
Publicado: (2021)

Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Relapse of neuromyelitis optica spectrum disorder after BNT162b2 mRNA Covid-19 vaccination
por: Wang, Qi, et al.
Publicado: (2023)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ek7lnjc05vl7pn256vm2hot22